Complete 2014 Induced Pluripotent Stem Cell (iPSC) Industry Report

News provided by

Research and Markets

14 Feb, 2014, 12:57 GMT

DUBLIN, Feb. 14, 2014 /PRNewswire/ --Research and Markets (http://www.researchandmarkets.com/research/dkdxtf/complete_201314) has announced the addition of the "Complete 2014 Induced Pluripotent Stem Cell (iPSC) Industry Report" report to their offering.

(Logo: http://photos.prnewswire.com/prnh/20130307/600769)

Stem cell research and experimentation has been in process for well over five decades, as stem cells have the unique ability to divide and replicate repeatedly. In addition, their unspecialized nature allows them to differentiate into a wide variety of specialized cell types. The possibilities arising from these characteristics have caused great commercial interest, with potential applications ranging from the use of stem cells in reversal or treatment of disease, to targeted cell therapy, tissue regeneration, pharmacological testing on cell-specific tissues, and more. Diseases such as Huntington's Chorea, Parkinson's Disease, and spinal cord injuries are examples of clinical applications in which stem cells could offer benefits in halting or even reversing damage.

Traditionally, scientists have worked with both embryonic and adult stem cells as research tools. While the appeal of embryonic cells has been their ability to differentiate into any type of cell, there has been significant ethical, moral and spiritual controversy surrounding their use for research purposes. Although some adult stem cells do have differentiation capacity, it is often limited in nature, which creates narrow options for use. Thus, induced pluripotent stem cells represent a promising combination of adult and embryonic stem cell characteristics.

Discovery:

Groundbreaking experimentation in 2006 led to the introduction of induced pluripotent stem cells (iPSC). These are adult cells which are isolated and then transformed into embryonic-like stem cells through the manipulation of gene expression, as well as other methods. Research and experimentation using mouse cells at Kyoto University in Japan was the first instance in which there was successful generation of the iPSC. In 2007, a series of follow-up experiments were done at Kyoto University in which human adult cells were transformed into iPSC cells.

While there has been continued excitement at the prospect of what such artificially re-manufactured cells could contribute to medical advances, there have also been issues along the way. By 2010, there were a number of private companies that were ready to capitalize on the breakthrough technology that iPSCs represent. One such company, Advanced Cell Technology in Worcester, Massachusetts, discovered several problematic issues while conducting experiments for the purpose of applying for U.S. Food and Drug Administration approval to use iPSCs in therapeutic applications. Concerns such as premature cell death, mutation into cancer cells, and low proliferation rates were some of the problems that surfaced.

Key Topics Covered:

I. ABSTRACT

II. BACKGROUND

III. TIMELINE

IV. RESEARCH APPLICATIONS

V. CHARACTERIZATION OF iPSC RESEARCH ADVANCES

VI. COMPANIES SELLING iPSC RESEARCH PRODUCTS

VII. TYPES OF iPSC RESEARCH PRODUCTS

VIII. COMPANIES DEVELOPING iPSC THERAPIES

IX. STRATEGIC COLLABORATIONS FOR DEVELOPMENT OF iPSC PRODUCTS

X. MARKET TREND ANALYSIS

XI. MARKET SIZE

XII. SCIENTIST PANEL: DETAILED END-USER SURVEY

XIII. STRATEGIES FOR ACCESSING THE MARKETPLACE

XIV. CONCLUSIONS

Companies Mentioned:

  • ArunA Biomedical
  • CeeTox and Cellular Dynamics
  • Cellular Dynamics
  • EMD Millipore
  • Fate Therapeutic
  • iPerian
  • Life Technologies
  • Lonza Group AG
  • Mesoblast
  • Roslin Cells, Ltd.
  • Sigma Aldrich
  • ViaCyte

For more information visit http://www.researchandmarkets.com/research/dkdxtf/complete_201314

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net